Cite
Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial
MLA
Wu, Jingying, et al. “Safety, Pharmacokinetics and Pharmacodynamics of HRS‐7535, a Novel Oral Small Molecule Glucagon‐like Peptide‐1 Receptor Agonist, in Healthy Participants: A Phase 1, Randomized, Double‐blind, Placebo‐controlled, Single‐ and Multiple‐ascending Dose, and Food Effect Trial.” Diabetes, Obesity & Metabolism, vol. 26, no. 3, Mar. 2024, pp. 901–10. EBSCOhost, https://doi.org/10.1111/dom.15383.
APA
Wu, J., Zhou, R., Zhang, Q., Zhang, Q., Qin, H., Ye, Z., Xu, Y., Feng, S., Shu, C., Shen, Y., Fan, Y., Wang, Q., Du, Y., & Hu, W. (2024). Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial. Diabetes, Obesity & Metabolism, 26(3), 901–910. https://doi.org/10.1111/dom.15383
Chicago
Wu, Jingying, Renpeng Zhou, Qian Zhang, Qin Zhang, Huiling Qin, Zi Ye, Yimei Xu, et al. 2024. “Safety, Pharmacokinetics and Pharmacodynamics of HRS‐7535, a Novel Oral Small Molecule Glucagon‐like Peptide‐1 Receptor Agonist, in Healthy Participants: A Phase 1, Randomized, Double‐blind, Placebo‐controlled, Single‐ and Multiple‐ascending Dose, and Food Effect Trial.” Diabetes, Obesity & Metabolism 26 (3): 901–10. doi:10.1111/dom.15383.